Telangana Today: Mapmygenome, Lucid launch DNA Onco Screen
All packages include genetic counselling to help understand individuals’ risk of cancer, inheritance patterns, and lifestyle changes essential to prevent cancer
Hyderabad: Lucid Diagnostics has partnered with Mapmygenome, a molecular diagnostics company, to advance personalised and preventive cancer care by combining genomics and pathology lab services. Lucid will offer DNA Onco Screen to customers and physicians for prevention and early detection of cancers.
The genetic risk assessment will be available through the partnership for cancers such as colorectal, prostrate, lung, breast, bladder, melanoma, renal cell carcinoma, ovarian, thyroid, chronic lymphocytic leukemia, hodgkins lymphoma, non-hodgkins lymphoma, pancreatic, basal cell carcinoma and testicular cancer.
“By looking at DNA as well as biochemical makers, DNA Onco Screen helps one understand lifetime genetic risks for a wide spectrum of cancers, early detection and roadmap for personalised, precise and preventive cancer management strategy.
Genetics is an important part of clinical diagnostics,” said Dr Sunitha Lingareddy, MD, Lucid Diagnostics.
Mapmygenome CEO Anu Acharya told Telangana Today, “Combining clinical parameters with genomics will help offer a comprehensive screen. We have spent almost 12-18 months to come out with this test. Lucid has a network of 100 centres and this partnership will improve access to cancer screening.
When asked what role each partner will play, she said, “Mapmygenome will collect the samples and do genetic counseling. We will identify the history and vulnerability each individual has to cancer. With the help of radiology, we wanted to make the tests comprehensive. We also wanted to provide something below Rs 10,000 to make it accessible. We want to provide a first step for screening. We will sensitise people to invest in health. Going forward, we will explore if we can integrate this to diabetes tests which is another major concern.”
DNA Onco Screen will help assess genetic predisposition of individuals to various cancers, physiological traits known to trigger cancer, and lifestyle traits linked to cancer risk. Key clinical markers associated with cancer are also tested.
There will be three board packages- DNA OncoScreen Pro is priced at Rs 9,999, DNA OncoScreen Plus at Rs 15,999 and DNA OncoScreen Premium at Rs 19,999. While biochemical tests are conducted in Pro and Plus packages, the Premium package will include radiology tests (in addition to biochemical tests) that will include mammography, chest x-ray and ultrasound abdomen.
All packages include genetic counselling to help understand individuals’ risk of cancer, inheritance patterns, and lifestyle changes essential to prevent cancer.
Originally published: https://telanganatoday.com/mapmygenome-lucid-launch-dna-onco-screen
Publication date: February 22, 2019